ADMA Biologics (United States)

company in Ramsey, United States

ADMA Nasdaq SEC CIK 1368514
Follow ADMA Biologics (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $141.1M +5.1% vs same quarter last year
Net income $49.9M +36.9% vs same quarter last year
EPS, diluted $0.22 +46.7% vs same quarter last year
Operating cash flow $17.4M +30.7% vs same quarter last year
Revenue by quarter
$117.5M
$114.8M
$122M
$134.2M
$139.2M
$114.5M
$124.4M
$141.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$510.2M$146.9M
FY24$426.5M$197.7M
FY23$258.2M−$28.2M
FY22$154.1M−$65.9M
FY21$80.9M−$71.7M
FY20$42.2M−$75.7M
FY19$29.3M−$48.3M
FY18$17M−$65.7M
FY17$22.8M−$43.8M
FY16$10.7M−$19.5M
FY15$7.2M−$18M
FY14$5.9M−$16.8M
FY13$3.1M−$15.5M
FY12$1.1M−$7.3M
FY11$761K−$5.9M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1000%−750%−500%−250%0%250%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2557.4%37.5%28.8%
FY2451.5%32.6%46.4%
FY2334.4%8.4%−10.9%
FY2222.9%−25.5%−42.8%
FY211.4%−72.1%−88.5%
FY20−45.2%−153.8%−179.4%
FY19−34.6%−141.1%−164.5%
FY18−148.4%−354.9%−387.1%
FY17−28.1%−172.7%−192.3%
FY1640.3%−162.6%−183.1%
FY1539.9%−216.1%−250.4%
FY1436.7%−270.8%−284.2%
FY1334%−490.4%−506.2%
FY1240.2%−707.4%−653%
FY1172.7%−607.5%−775.7%
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$27.8M
FY24$110.4M
FY23$4M
FY22−$73.4M
FY21−$125.9M
FY20−$114.7M
FY19−$80M
FY18−$64.8M
FY17−$39.9M
FY16−$18.3M
FY15−$15.4M
FY14−$17M
FY13−$11.1M
FY12−$7M
FY11−$1.4M
Returned to shareholdersDividends paid and shares bought back
$0$10M$20M$30M$40MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$31.9M
FY24$0
FY23$0
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12$150K
FY11$0
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • ADMA Biologics (United States)
  • Healthcare median
−1000%−750%−500%−250%0%250%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearADMA Biologics (United States)Healthcare median
FY2528.8%−30.6%
FY2446.4%−47%
FY23−10.9%−58%
FY22−42.8%−80.4%
FY21−88.5%−71.8%
FY20−179.4%−62.2%
FY19−164.5%−46.2%
FY18−387.1%−49.6%
FY17−192.3%−45.9%
FY16−183.1%−36%
FY15−250.4%−37.8%
FY14−284.2%−35.5%
FY13−506.2%−37.1%
FY12−653%−29.1%
FY11−775.7%−27.9%